Cargando…

Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey

BACKGROUND: Cyproterone acetate 2 mg/ethinylestradiol 35 µg, an estrogen/progestogen treatment with anti-androgenic properties, shares a thromboembolism risk with combined hormonal contraceptives. Educational materials (i.e., direct healthcare professional communication, patient information card, pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davis, Kimberly H., Asiimwe, Alex, Zografos, Laurie J., McSorley, David J., Andrews, Elizabeth B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629244/ https://www.ncbi.nlm.nih.gov/pubmed/29056853 http://dx.doi.org/10.1007/s40290-017-0203-9

Ejemplares similares

Women consuming oral contraceptives containing cyproterone acetate and ethinylestradiol show a higher risk of thyroid cancer than nonusers
por: Lai, Pei-Hsuan, et al.
Publicado: (2023)

Voltammetric Determination of Cyproterone Acetate in Pharmaceutical Preparations
por: El-Enany, Nahed, et al.
Publicado: (2010)

Clinical behavior of a cohort of adult women with facial acne treated with combined oral contraceptive: ethinylestradiol 20 µg/dienogest 2 mg
por: Palacio-Cardona, John, et al.
Publicado: (2017)

Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
por: Klipping, Christine, et al.
Publicado: (2012)

Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
por: Klipping, Christine, et al.
Publicado: (2012)

Cyproterone acetate acts as a disruptor of the aryl hydrocarbon receptor
por: Chen, Chih-Shou, et al.
Publicado: (2021)

Ethinylestradiol/Chlormadinone Acetate: Dermatological Benefits
por: Guerra-Tapia, Aurora, et al.
Publicado: (2012)

Efficacy of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study
por: Strowitzki, Thomas, et al.
Publicado: (2012)

A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma.
por: Keating, J. J., et al.
Publicado: (1989)

Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders
por: Vázquez, Mercedes Gómez, et al.
Publicado: (2012)

Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People’s Republic of China: a comparison with international studies
por: Marr, Joachim, et al.
Publicado: (2015)

Unilateral proptosis and blindness caused by meningioma in a patient treated with cyproterone acetate
por: Sys, Celine, et al.
Publicado: (2015)

Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy
por: Montani, David, et al.
Publicado: (2014)

SAT397 A Low Dose Cyproterone Acetate In Feminizing Hormone Treatment
por: Korpaisarn, Sira, et al.
Publicado: (2023)

A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas
por: Lee, Keng Siang, et al.
Publicado: (2022)

Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy
por: Angus, Lachlan, et al.
Publicado: (2019)

SUN-042 Low Dose Cyproterone Acetate for the Treatment of Transgender Women - a Retrospective Study
por: Even-Zohar, Naomi, et al.
Publicado: (2020)

The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study.
por: Thompson, P., et al.
Publicado: (1991)

Regression of Giant Olfactory Groove Meningioma and Complete Visual Acuity Recovery after Discontinuation of Cyproterone Acetate
por: Bernat, Anne Laure, et al.
Publicado: (2018)

Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
por: Portet, Sylvain, et al.
Publicado: (2019)

Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study
por: Kuijpers, Suzanne M E, et al.
Publicado: (2021)

Double-Blind, Placebo-Controlled Trial of Cyproterone Acetate to Prevent Flare-Up Effect on Dogs Implanted With Deslorelin
por: Masson, Sylvia, et al.
Publicado: (2021)

The use of cyproterone acetate in a forensic psychiatric cohort of male sex offenders and its associations with sexual activity and sexual functioning
por: Lippi, Gian, et al.
Publicado: (2017)

Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial
por: Adalatkhah, Hassan, et al.
Publicado: (2011)

Cyproterone Acetate Mediates IRE1α Signaling Pathway to Alleviate Pyroptosis of Ovarian Granulosa Cells Induced by Hyperandrogen
por: Zhang, Yan, et al.
Publicado: (2022)

Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016)

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis
por: Yoo, Jun-Il, et al.
Publicado: (2017)

Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5
por: Chen, Linjie, et al.
Publicado: (2017)

Using cyproterone acetate to treat recurrent ischemic priapism in a patient with sickle cell anemia as a comorbidity: a case report
por: Alshahrani, Ali
Publicado: (2020)

Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0.4 µg/L but < 1 µg/L
por: Rosario, Pedro Weslley, et al.
Publicado: (2017)

Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women with polycystic ovary syndrome: a randomized controlled trial
por: Behboudi-Gandevani, Samira, et al.
Publicado: (2019)

Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen)
por: Bitzer, Johannes, et al.
Publicado: (2015)

Effectiveness of 190 µg Fluocinolone Acetonide and 700 µg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
por: Zarranz-Ventura, Javier, et al.
Publicado: (2020)

The Efficacy of the Yasmin[Ethinylestradiol-Drospirenone (0.03/3 mg)] Treatment for Postoperative Abortion: A Protocol of Meta-Analysis
por: Tian, Tian, et al.
Publicado: (2022)

Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg ‐levonorgestrel 0.09 mg for dysmenorrhea: A placebo‐controlled, double‐blind, randomized trial
por: Harada, Tasuku, et al.
Publicado: (2021)

Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women
por: Blode, Hartmut, et al.
Publicado: (2012)

Inhibitory effect of ethinylestradiol on coagulation factors in rats
por: Franco-Murillo, Yanira, et al.
Publicado: (2016)

Bleeding Pattern and Management of Unexpected Bleeding/Spotting with an Extended Regimen of a Combination of Ethinylestradiol 20 mcg and Drospirenone 3 mg
por: Bonassi Machado, Rogerio, et al.
Publicado: (2020)

Micromachined Accelerometers with Sub-µg/√Hz Noise Floor: A Review
por: Wang, Chen, et al.
Publicado: (2020)

The Role of Non-Cognate T Cell Stimulation during Intracellular Bacterial Infection
por: McSorley, Stephen J.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mitvcsghrkbl1fhtrhclj1mus5